| 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer (NCT05547386) | Mayo Clinic | 2022-05-09 |
| Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients (NCT05045066) | Mayo Clinic | 2021-12-29 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer (NCT04716725) | Thomas Hope | 2021-09-28 |
| 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression (NCT04927663) | Rahul Aggarwal | 2021-08-10 |
| 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy (NCT04928820) | Jonsson Comprehensive Cancer Center | 2021-06-16 |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations (NCT04550494) | National Cancer Institute (NCI) | 2021-04-26 |
| Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer (NCT04489719) | University of Washington | 2021-04-16 |
| Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial (NCT04693377) | M.D. Anderson Cancer Center | 2021-03-16 |
| Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer (NCT04592237) | M.D. Anderson Cancer Center | 2020-12-29 |
| Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study (NCT04585932) | M.D. Anderson Cancer Center | 2020-11-24 |
| National Cancer Institute "Cancer Moonshot Biobank" (NCT04314401) | National Cancer Institute (NCI) | 2020-11-11 |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging (NCT04423211) | ECOG-ACRIN Cancer Research Group | 2020-10-08 |
| Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study (NCT04447703) | Thomas Jefferson University | 2020-08-27 |
| DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers (NCT04388852) | M.D. Anderson Cancer Center | 2020-08-20 |
| Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer (NCT03649841) | University of Washington | 2020-06-29 |
| Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer (NCT04267887) | OHSU Knight Cancer Institute | 2020-05-11 |
| Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer (NCT03999515) | University of Washington | 2020-04-27 |
| Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer (NCT04279561) | Jonsson Comprehensive Cancer Center | 2020-04-16 |
| An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer (NCT04134208) | M.D. Anderson Cancer Center | 2019-09-19 |
| PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer (NCT03873805) | City of Hope Medical Center | 2019-08-20 |
| Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer (NCT03751436) | Roswell Park Cancer Institute | 2019-08-02 |
| Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients (NCT03987217) | University of Utah | 2019-06-17 |
| M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT03517969) | National Cancer Institute (NCI) | 2019-05-29 |
| 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT03805594) | University of California, San Francisco | 2019-05-10 |
| PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery (NCT03218826) | National Cancer Institute (NCI) | 2018-09-24 |
| Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy (NCT03596710) | Jonsson Comprehensive Cancer Center | 2018-06-14 |
| 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer (NCT04050215) | Jonsson Comprehensive Cancer Center | 2018-04-02 |
| ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer (NCT03456804) | Barbara Ann Karmanos Cancer Institute | 2018-03-08 |
| Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer (NCT03448458) | Emory University | 2018-02-22 |
| Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer (NCT02881242) | Jonsson Comprehensive Cancer Center | 2018-01-30 |
| Genetic Testing for Men With Metastatic Prostate Cancer (NCT03503097) | University of Washington | 2017-08-21 |
| Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer (NCT02893917) | National Cancer Institute (NCI) | 2017-08-11 |
| Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies (NCT03217747) | M.D. Anderson Cancer Center | 2017-08-02 |
| Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer (NCT03016741) | Northwestern University | 2017-03-31 |
| Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer (NCT02935205) | Mamta Parikh | 2017-01-17 |
| Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects (NCT03012321) | Northwestern University | 2017-01-12 |
| Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer (NCT03123978) | University of California, Davis | 2017-01-09 |
| Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients (NCT03011749) | Rigshospitalet, Denmark | 2017-01-01 |
| Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer (NCT02807805) | Mamta Parikh | 2016-10-01 |
| Carbon Ion Radiotherapy in Treating Patients Undergoing Systemic Therapy for Oligo-metastatic Prostate Cancer (NCT02935023) | Shanghai Proton and Heavy Ion Center | 2016-09-01 |
| Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer (NCT02516670) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-06-20 |
| Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients (NCT02853097) | University of Southern California | 2016-06-14 |
| Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT02703623) | M.D. Anderson Cancer Center | 2016-05-18 |
| A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients (NCT02691975) | Jiangsu HengRui Medicine Co., Ltd. | 2016-04-12 |
| Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT02565901) | University of Washington | 2016-02-29 |
| Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway (NCT02598895) | University of Washington | 2016-01-26 |
| Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer (NCT02532114) | University of Washington | 2015-12-31 |
| Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression (NCT02555189) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2015-12-01 |
| Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel (NCT02491411) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-09-01 |
| Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer (NCT02522715) | OHSU Knight Cancer Institute | 2015-08-13 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer (NCT02499835) | University of Wisconsin, Madison | 2015-07-01 |
| Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer (NCT02458716) | Rutgers, The State University of New Jersey | 2015-03-06 |
| Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT02159950) | Roswell Park Cancer Institute | 2015-01-01 |
| Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer (NCT02370355) | University of Southern California | 2014-12-23 |
| CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT01881867) | Fred Hutchinson Cancer Center | 2013-09-10 |
| Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy (NCT01953640) | Mayo Clinic | 2013-05-30 |
| Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01503229) | University of Washington | 2012-12-01 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (NCT01522820) | Roswell Park Cancer Institute | 2012-03-01 |
| Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer (NCT00942331) | National Cancer Institute (NCI) | 2009-07-15 |